Randomized, open-label, multiple-dose study to evaluate the pharmacokinetics of atazanavir administered twice-daily in health subjects.
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2011
At a glance
- Drugs Atazanavir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 01 Nov 2007 Status changed from in progress to completed.
- 03 Nov 2006 New trial record.